BridgeBio Pharma, Inc.
As of Oct 22, 2026, BridgeBio Pharma is in Stage 4, the downtrend phase, now in its first week (since Oct 16, 2026). It closed at $68.12, 24.5% below its 52-week high and below its 200-day average, which is falling.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BBIO among Biotechnology127th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …127 | BBIO | Stage 4 · wk 1 | 73 | +3.7% |
BridgeBio Pharma: quick answers
What stage is BridgeBio Pharma in?
As of Oct 22, 2026, BridgeBio Pharma (BBIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 16, 2026 and is in its first week there. What the four stages mean
Is BridgeBio Pharma in an uptrend?
No. BridgeBio Pharma is in a Stage 4 downtrend. It trades 6.6% below its 200-day average, which is falling.
How far is BridgeBio Pharma from its 52-week high?
BridgeBio Pharma closed at $68.12 on Oct 22, 2026, 24.5% below its 52-week high of $90.17. Its 52-week low is $53.24.
How has BridgeBio Pharma performed over the past year?
As of Oct 22, 2026, BridgeBio Pharma is up 25.3% over the past year and down 12.9% so far in 2026.
Which sector and industry is BridgeBio Pharma in?
BridgeBio Pharma is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.